Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

被引:1
|
作者
Yu, Jiahui [1 ]
Yan, Duan [1 ]
Wei, Song [1 ]
Yang, Linfeng [1 ]
Yi, Pengsheng [1 ]
机构
[1] North Sichuan Med Coll, Affiliated Hosp, Dept Hepatobiliary Pancreas 2, 1 Maoyuan South Rd, Nanchong 637000, Sichuan, Peoples R China
关键词
transcatheter arterial chemoembolization; tyrosine kinase inhibitors; camrelizumab; hepatocellular carcinoma; meta-analysis; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; TRANSARTERIAL CHEMOEMBOLIZATION; DOUBLE-BLIND; MULTICENTER; APATINIB; THERAPY; ANTIBODIES; LENVATINIB; TRIALS;
D O I
10.3892/ol.2024.14534
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transcatheter arterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and camrelizumab (collectively: T-T-C) is a novel treatment strategy for unresectable hepatocellular carcinoma (HCC). The present systematic review and meta-analysis aimed to evaluate the efficacy and safety of T-T-C compared with TACE combined with TKIs only (T-T) in the treatment of patients with unresectable HCC. A systematic literature search was conducted on T-T and T-T-C using PubMed, Embase and the Cochrane Library. Data regarding the clinical outcome, including overall survival (OS), progression-free survival (PFS), tumor response and adverse events (AEs), were independently extracted and analyzed by two researchers using standardized protocols. In total, 7 cohort studies, including 1,798 patients (T-T-C, 838; T-T, 960), were included in the meta-analysis. The results of the present study demonstrated that the T-T-C group had significantly prolonged OS [hazard ratio (HR), 0.38; 95% confidence interval (CI), 0.29-0.50; I2=61.5%; P=0.016)] and PFS (HR, 0.37; 95% CI, 0.30-0.46; I2=44.5%; P=0.109), and showed significantly higher objective response rates [risk ratio (RR), 0.82; 95% CI, 0.69-0.96; I2=25.1%; P=0.237)] and slightly higher disease control rates without a significant difference (RR, 0.96; 95% CI, 0.89-1.03; I2=0.0%; P=0.969). In addition, grade 3/4 AEs were more common in the T-T group, including hypertension (RR, 1.15; 95% CI, 0.85-1.56), vomiting or nausea (RR, 0.88; 95% CI, 0.44-1.76) and pain (RR, 0.74; 95% CI, 0.45-1.21); however, these results were not statistically significant. In conclusion, compared with T-T combination therapy, T-T-C demonstrated a notable advantage in terms of OS, PFS, ORR and DCR in patients with unresectable HCC. For manageable AEs, although the results were not statistically significant, the incidence of AEs in the T-T group was higher than that in the T-T-C group in terms of event probability.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Wang, Lei
    Ke, Qiao
    Lin, Nanping
    Huang, Qizhen
    Zeng, Yongyi
    Liu, Jingfeng
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2019, 36 (01) : 1287 - 1295
  • [22] Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Teng-Kai Yang
    Ya-Fang Yu
    Chiao-Ling Tsai
    Hsing-Ju Li
    Po-Sheng Yang
    Kai-Wen Huang
    Jason Chia-Hsien Cheng
    BMC Cancer, 22
  • [23] Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Yang, Teng-Kai
    Yu, Ya-Fang
    Tsai, Chiao-Ling
    Li, Hsing-Ju
    Yang, Po-Sheng
    Huang, Kai-Wen
    Cheng, Jason Chia-Hsien
    BMC CANCER, 2022, 22 (01)
  • [24] Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma A Meta-analysis
    Jacome, Alexandre A.
    Castro, Ana Carolina G.
    Vasconcelos, Joao Paulo S.
    Silva, Maria Helena C. R.
    Lessa, Marco Antonio O.
    Moraes, Eduardo D.
    Andrade, Aline C.
    Lima, Frederico M. T.
    Farias, Joao Paulo F.
    Gil, Roberto A.
    Prolla, Gabriel
    Garicochea, Bernardo
    JAMA NETWORK OPEN, 2021, 4 (12) : E2136128
  • [25] Efficacy and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy or Tyrosine Kinase Inhibitors in Advanced Endometrial Cancer: A Systematic Review and Meta-Analysis
    Li, Yuting
    Li, Shixiu
    Liang, Juan
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2024,
  • [26] TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis
    Liu, Jiaxi
    Wang, Peng
    Shang, Liqi
    Zhang, Zhoubo
    Tian, Yulong
    Chen, Xiaowei
    Ma, Yanan
    Shao, Haibo
    HEPATOLOGY INTERNATIONAL, 2024, 18 (02) : 595 - 609
  • [27] TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis
    Jiaxi Liu
    Peng Wang
    Liqi Shang
    Zhoubo Zhang
    Yulong Tian
    Xiaowei Chen
    Yanan Ma
    Haibo Shao
    Hepatology International, 2024, 18 : 595 - 609
  • [28] Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues
    Yang, Shiye
    Liang, Huoqi
    Li, Xing
    Qian, Jiayi
    Ming, Zhibing
    HEPATOLOGY INTERNATIONAL, 2024, 18 (04) : 1336 - 1337
  • [29] TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
    Tang, Zhihong
    Bai, Tao
    Wei, Tao
    Wang, Xiaobo
    Chen, Jie
    Ye, Jiazhou
    Li, Shangqi
    Wei, Meng
    Li, Xingzhi
    Lin, Youzhi
    Tang, Juan
    Li, Lequn
    Wu, Feixiang
    BMC CANCER, 2024, 24 (01)
  • [30] The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis
    Ma, Xiao
    Li, Rui-Sheng
    Wang, Jian
    Huang, Yin-Qiu
    Li, Peng-Yan
    Wang, Ji
    Su, Hai-Bin
    Wang, Rui-Lin
    Zhang, Ya-Ming
    Liu, Hong-Hong
    Zhang, Cong-En
    Ma, Zhi-Jie
    Wang, Jia-Bo
    Zhao, Yan-Ling
    Xiao, Xiao-He
    FRONTIERS IN PHARMACOLOGY, 2016, 7